Profluent

Market position

Sources position Profluent as an early mover in generative AI for protein design, citing firsts in demonstrating that large language models can generate functional proteins (Nature Biotechnology, 2023), designing a CRISPR system from scratch with AI (Nature, 2025), and establishing scaling laws for protein design (NeurIPS spotlight, 2025). An investor quoted in the funding coverage frames the company as a frontier science company addressing programmable biology markets.

The company emphasizes the combination of frontier foundation models with an integrated in-house wet lab, the scale of its Protein Atlas dataset, the ability to optimize multiple protein attributes simultaneously, and access to sequence space outside natural or patented proteins. Its open-sourcing of OpenCRISPR-1 is presented as evidence of validated, deployed AI-designed molecules.

Technology

Profluent builds frontier foundation models for protein sequence generation, including large language models for protein generation, ProseLM for structure-conditioned design, and models for CRISPR-Cas PAM prediction and customization. Key publications cited by the company include "Design of highly functional genome editors by modelling CRISPR-Cas sequences," "Large Language Models Generate Functional Protein Sequences Across Diverse Families," and "Deep Extrapolation for Attribute-Enhanced Generation." The models are trained against the company's Protein Atlas of more than 115 billion unique proteins and are coupled to an in-house wet lab for experimental validation.

Go-to-market

The company markets primarily through partnerships with established industry players and through scientific publication and open-sourcing. Peer-reviewed results (Nature Biotechnology 2023, Nature 2025, NeurIPS spotlight 2025) and the freely available OpenCRISPR-1 editor serve as technical validation, while a dedicated general manager role for Biologics & Models, added in 2025, is tasked with expanding partnerships beyond genome editors.

Pharmaceutical and biotechnology companies, agricultural science firms, diagnostics and life-science tools providers, disease-focused research foundations, and academic researchers.

Geography

Headquartered in Emeryville, California, United States.

History

Founded in 2022 in Emeryville, California. The company published work in Nature Biotechnology in 2023 showing large language models can generate functional proteins. In April 2024 its AI-designed CRISPR work received mainstream press coverage, and the resulting OpenCRISPR-1 editor was released as open source; the associated CRISPR-Cas design paper appeared in Nature in 2025, alongside a NeurIPS spotlight on scaling laws for protein design. In November 2025 the company announced a $106 million financing co-led by Altimeter Capital and Bezos Expeditions, bringing total funding to $150 million, and expanded its commercial scope beyond genome editors into antibodies, antigens, and enzymes.

Risks & controversies

No controversies or disputes are reported in the available sources. Reporting is inconsistent on the November 2025 financing: most sources describe a $106 million round bringing cumulative funding to $150 million, while one aggregator characterizes $150 million as new funding and labels it a grant, and lists investors (AIX Ventures, Convergent Ventures) not named in the primary announcement. The company's stated objective of an AI-designed therapeutic reaching human patients remains unachieved, and claims such as the Protein Atlas being the world's largest protein data resource are company-provided.